The prognostic value of ADRA1 subfamily genes in gastric carcinoma

Adrenergic receptor α1 (ADRA1) subfamily members, including ADRA1A, ADRA1B and ADRA1D, are understood to participate in cardiac disease and benign prostatic hyperplasia. In addition, adrenergic signals in cell pathways can promote the development of cancer. However, little is understood regarding th...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2019-09, Vol.18 (3), p.3150-3158
Main Authors: Wang, Tingan, Qin, Yuzhou, Lai, Hao, Wei, Weiyuan, Li, Zhao, Yang, Yang, Huang, Mingwei, Chen, Jiansi
Format: Article
Language:English
Subjects:
Age
Analysis
Biochemistry
Cancer
Cancer genetics
Cancer therapies
Carcinoma
Cardiovascular diseases
Confidence intervals
Development and progression
Gastric cancer
Gene expression
Genes
Genetic aspects
Genomes
Genomics
Hyperplasia
Kinases
Medical prognosis
Messenger RNA
Metastasis
Mortality
Oncology
Operating systems (Software)
Patients
Prognosis
Prostatic hyperplasia
Proteins
Regression analysis
RNA
Stomach cancer
Studies
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adrenergic receptor α1 (ADRA1) subfamily members, including ADRA1A, ADRA1B and ADRA1D, are understood to participate in cardiac disease and benign prostatic hyperplasia. In addition, adrenergic signals in cell pathways can promote the development of cancer. However, little is understood regarding the associations between ADRA1 subfamily members and gastric carcinoma (GC). The present study investigated the prognostic value of the ADRA1 subfamily genes in GC. Data from a total of 379 patients with GC were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. Kaplan-Meier analysis and Cox regression analysis were used to determine associations with overall survival (OS) and to evaluate the median survival time using hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariate survival analysis revealed that low expression levels of ADRA1A (HR, 0.595; 95% CI, 0.426-0.831; adjusted P=0.002) ADRA1B (HR, 0.576; 95% CI, 0.412-0.805; adjusted P=0.001) and ADRA1D (HR, 0.559; 95% CI, 0.398-0.787; adjusted P=0.001) were associated with a favourable OS. Joint-effects analysis demonstrated that combinations of low expression levels of ARDA1A, ARDA1B and ARDA1D were significantly associated with a favourable OS. Overall, the current results suggested that the mRNA expression levels of ARDA1 subfamily members may serve as potential prognostic markers for GC.
ISSN:1792-1074
1792-0981
1792-1082
DOI:10.3892/ol.2019.10660